Objective:To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of gastric cancer with peritoneal carcinomatosis.Methods:The relevant clinical controlled studies were ...Objective:To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of gastric cancer with peritoneal carcinomatosis.Methods:The relevant clinical controlled studies were retrieved from the databases of PubMed,Cochrane Library,Embase.Risk ratio(RR),as well as the respective 95%confidence interval(CI),was used as a statistical indicator.1-year survival,2-year survival,and safety were analyzed.Results:Two randomized controlled trials(RCTs)and 10 high-quality non-randomized controlled trials(NRCTs)were included,enrolling 837 patients(438 in the HIPEC group and 415 in the control group).Compared with the control group,HIPEC group turned out to be of greater improvement in long-term efficacy:1-year survival rate(1y-os)and 2-year survival rate(2y-os).Subgroup analysis of different treatment modes in NRCTs showed that,in terms of 1-year survival rate,(1)HIPEC combined with cytoreductive surgery(CRS)compared with CRS alone,RR=0.68,95%CI:(0.53,0.85);(2)HIPEC combined with intravenous chemotherapy±CRS versus chemotherapy alone,RR=0.54,95%CI:(0.39,0.74);(3)HIPEC combined with palliative gastrectomy versus palliative gastrectomy,RR=0.37,95%CI:(0.22,0.63).As for safety,there were no significant differences in adverse events between two groups.Conclusion:HIPEC can prolong the survival of gastric cancer patients with peritoneal carcinomatosis,and the incidences of adverse events were not increased.展开更多
文摘Objective:To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of gastric cancer with peritoneal carcinomatosis.Methods:The relevant clinical controlled studies were retrieved from the databases of PubMed,Cochrane Library,Embase.Risk ratio(RR),as well as the respective 95%confidence interval(CI),was used as a statistical indicator.1-year survival,2-year survival,and safety were analyzed.Results:Two randomized controlled trials(RCTs)and 10 high-quality non-randomized controlled trials(NRCTs)were included,enrolling 837 patients(438 in the HIPEC group and 415 in the control group).Compared with the control group,HIPEC group turned out to be of greater improvement in long-term efficacy:1-year survival rate(1y-os)and 2-year survival rate(2y-os).Subgroup analysis of different treatment modes in NRCTs showed that,in terms of 1-year survival rate,(1)HIPEC combined with cytoreductive surgery(CRS)compared with CRS alone,RR=0.68,95%CI:(0.53,0.85);(2)HIPEC combined with intravenous chemotherapy±CRS versus chemotherapy alone,RR=0.54,95%CI:(0.39,0.74);(3)HIPEC combined with palliative gastrectomy versus palliative gastrectomy,RR=0.37,95%CI:(0.22,0.63).As for safety,there were no significant differences in adverse events between two groups.Conclusion:HIPEC can prolong the survival of gastric cancer patients with peritoneal carcinomatosis,and the incidences of adverse events were not increased.
